Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial.
Saved in:
| Title: | Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial. |
|---|---|
| Authors: | Zou, Qihua1,2 (AUTHOR), Cao, Yi1,2 (AUTHOR), Lai, Yulin1,2 (AUTHOR), Fang, Yu3,4 (AUTHOR), Zhang, Yuchen1,2 (AUTHOR), Liu, Panpan1,2 (AUTHOR), Lu, Lixia1,5 (AUTHOR), Wu, Hao6 (AUTHOR), Huang, Tianying7 (AUTHOR), Su, Ning8 (AUTHOR), Li, Zhihua3,4 (AUTHOR), Wang, Xicheng9 (AUTHOR), Tian, Xiaopeng1,2 (AUTHOR), Li, Lirong1,2 (AUTHOR), Liu, Yingxian1,2 (AUTHOR), Cai, Qingqing1,2 (AUTHOR) caiqq@sysucc.org.cn, Xia, Yi1,2 (AUTHOR) xiayi@sysucc.org.cn |
| Source: | BMC Medicine. 5/6/2025, Vol. 23 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17417015 |
|---|---|
| DOI: | 10.1186/s12916-025-04103-0 |
